Effectiveness of peritonsillar bupivacaine versus lignocaine infiltration for post-tonsillectomy pain management in children at Kilimanjaro Christian medical Centre A double-blind randomized placebo-controlled superiority trial

Effectiveness of peritonsillar bupivacaine versus lignocaine infiltration for post-tonsillectomy pain management in children at Kilimanjaro Christian medical Centre: A double-blind randomized placebo-controlled superiority trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202408714414101

Enrollment

150

Registered

2024-08-27

Start date

2024-08-31

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ear, Nose and Throat

Interventions

Lignocaine

Bupivacaine

Saline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All children aged <18 years admitted for elective tonsillectomy at ENT department in KCMC Hospital from September 2024 to June 2025 whose parents consented for their children to be included on the study.

Exclusion criteria

Exclusion criteria: 1. Patient having severe systemic disease (ASA classification more than 2) 2. Known allergy to any of the study drugs 3. Under chronic analgesic treatment 4. Psychomotor retardation 5. Undergoing one-sided tonsillectomy, tonsillectomy of known cancer, tonsillar biopsy, tonsillectomy due to peritonsillar abscess or tonsillectomy together with palatal surgery

Design outcomes

Primary

Measure	Time frame
Pain scores	—

Secondary

Measure	Time frame
Time until resumption of routine diet;Primary hemorrhage;Secondary hemorrhage;Use of additional analgesics;Nausea/Vomiting;Cardiac arrhythmias	—

Countries

United Republic of Tanzania

Contacts

Public ContactFadhili Samsoni

Resident Doctor

fadhilisamsoni@gmail.com+272751351

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026